All News
Filter News
Found 808,690 articles
-
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2022 Results
2/21/2023
Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2022 results.
-
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2/21/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
2/21/2023
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023.
-
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
2/21/2023
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading on Monday, March 6.
-
3H Medi Solution Selects THREAD to Expand Delivery of Decentralized Clinical Trials in Japan
2/21/2023
3H Medi Solution Inc., a leading Japanese clinical trial company, today announced its selection of THREAD to expand decentralized research capabilities and improve access to clinical research for patients in Japan.
-
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
2/21/2023
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023.
-
Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
2/21/2023
Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023.
-
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
2/21/2023
Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market.
-
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
2/21/2023
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming 43rd Annual Cowen Health Care Conference.
-
Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023
2/21/2023
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that it will release its financial results for fiscal year 2022 and provide a business update on Monday, February 27, 2023.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 22, 2023
2/21/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs) will be presenting at the Emerging Growth Conference on February 22, 2023.
-
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2/21/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2022.
-
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
2/21/2023
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022, and to provide a business update.
-
Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023
2/21/2023
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will participating in the 19th Annual WORLDSymposium™ 2023, taking place February 22–26, 2023 at the Hilton Orlando in Orlando, Florida.
-
Leal Health Presents Poster Highlighting Negative Impact of Patient ECOG Scores on Clinical Trial Enrollment Eligibility at 2023 ASCO GU Cancers Symposium
2/21/2023
Leal Health announced today that the Company presented a poster on the negative impact of Eastern Cooperative Oncology Group (ECOG) performance status scores on cancer patients' eligibility to enroll in clinical trials at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
-
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
2/21/2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.
-
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
2/21/2023
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology’s 72nd Annual Scientific Session together with World Heart Federation’s World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA from March 4-6, 2023.
-
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
2/21/2023
Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the year ended December 31, 2022.
-
Software-Based VUZE Surgical Guidance System Demonstrates Benefits in a 20-Patient Clinical Study
2/21/2023
VUZE Medical, a privately-held company aiming to transform intra-operative guidance in minimally invasive spinal interventions, has successfully concluded a 20-patient clinical study for its VUZE System evaluating safety, accuracy and user experience at the Rambam Healthcare Campus, a 1,000-bed academic hospital in Haifa, Israel.
-
ICU Medical to Present at the Raymond James 44th Annual Institutional Investors Conference
2/21/2023
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 44th Annual Institutional Investors Conference being held in Orlando, Florida, March 5-8, 2023.